Historically, SNM has been delivered using a non-rechargeable device with a lifespan of 3 -5 years, requiring surgery to replace the implanted neurostimulator due to battery depletion. Replacement surgery increases patient risks and health-care costs, which could be reduced by use of a long lived, rechargeable system. The Axonics r-SNM System, approved in Europe, Canada and Australia, is a miniaturized, rechargeable system designed to deliver therapy for at least 15 years. The ARTISAN-SNM study is a prospective, multi-center pivotal study conducted under an investigational device exemption from the US FDA with the purpose of gaining US marketing approval of the novel Axonics r-SNM System.
INTRODUCTION AND OBJECTIVES:
The eCoinÒ (Electroceutical Coin) (Valencia Technologies Corp., Valencia, CA, USA) is an investigational, implanted, battery-powered, slightly larger than a United States nickel in diameter (23.3 mm versus 21.2 mm) and thickness (2.4 mm versus 1.95 mm), neuromodulation device for the treatment of overactive bladder syndrome (OAB) with urgency urinary incontinence (UUI) in adults who have an inadequate response to or are intolerant of OAB medications by electrically stimulating the tibial nerve. The device can be implanted during an office-based procedure under local anesthesia, and does not require external stimulation.
This was a 12 month clinical feasibility trial to evaluate the longterm safety and efficacy of eCoinÒ tibial nerve stimulation to treat refractory UUI.
METHODS: The long-term (12 month) study was a prospective, single-arm, open-label study including 46 participants with refractory UUI, conducted at multiple sites in the US and New Zealand. The eCoinÒ was implanted in the lower leg over the tibial nerve and activated after 4 weeks. Bladder diary data and validated quality-oflife instruments, collected at 3, 6 and 12 months post-activation, were compared to baseline.
RESULTS: Mean age was 63.4 AE 11.5 years and 45 participants were female. Episodes of UUI were reduced by a median 68% after 12 months of treatment (4.2 versus 1.7 episodes/day at 12 months; p[.001). Overall, 30/46 participants (65%) experienced more than a 50% improvement in UUI. Of those participants, 8 experienced ! 75% improvement and 12 experienced 100% improvement. Incontinence quality of life (I-QOL) scores improved by a mean of 86%. A single serious adverse event, secondary to the provided ankle wrap, resolved with intravenous antibiotics.
CONCLUSIONS: The implantable eCoinÒ neuromodulation device showed durable efficacy and safety through 12 months and is a promising new treatment option for refractory OAB. 
LBA-07 EJACULATORY HOOD SPARING VS. STANDARD GREENLIGHTTM LASER PHOTOSELECTIVE VAPORIZATION OF THE PROSTATE: SEXUAL AND URODYNAMIC ASSESSMENT THROUGH RANDOMIZED CONTROLLED TRIAL (RCT)
Ahmed Elhussein Abolazm*, Ahmed M. Elshal, Ahmed S. Elhefnawy, Ahmed B. Shehab-El-Din, mansoura, Egypt INTRODUCTION AND OBJECTIVES: Ejaculatory dysfunction has been reported as a price for successful relief of benign prostatic obstruction. Attempts to preserve ejaculation have been described however; concerns about potential re-obstruction are never solved.
In this trial, we assessed the efficacy of EH-sparing Greenlight Laser photoselective vaporization of the prostate (GL.PVP) in preserving antegrade ejaculation and urodynamic relief of obstruction in comparison to standard GL.PVP.
METHODS: Between November 2015 and September 2017, 46 out of 50 sexually active BPH patients were randomized for the study. Standard GL.PVP was performed as classically described with TURP like cavity as end point of vaporization. EH-sparing GL.PVP was performed with preservation of the paracollicular and supracollicular tissue present proximal to verumontanum. Patients were assessed at baseline and postoperatively at 1, 6 and 12 months using Ej-MSHQ and IIEF-15. Urinary symptoms were assessed using IPSS-QoL, uroflow and PVR at baseline and different follow up points. Standard urodynamic study (UDS) was performed at 6 months.
RESULTS: At time of analysis, 24 EH-sparing GL.PVP and 22 standard GL.PVP procedures were evaluable. Antegrade ejaculation was reported in 85% after EH-sparing GL.PVP and in 31.6% after standard GL.PVP (P[0.001). Significant reduction in EJ-MSHQ score was reported after standard GL.PVP at 6 and 12 months (P<0.001, <0.001) with no significant difference after EH-sparing GL.PVP, (P[0.18, P[0.078) respectively. The median EJ-MSHQ score was 28.5 (1-33), 27 (1-33) in EH-sparing GL.PVP and 9.5 (1-35), 9 (0-33) in standard GL.PVP group at 6 (P[0.005) and 12 months (p<0.001) respectively. Both groups showed declined in mean total IIEF-15 score at 1 year however, this decline was statistically significant only after standard GL.PVP (p[0.001). All urinary outcome measures showed comparable significant improvement at all follow up points. Postoperative urodynamic
